PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Jan 25, 2024 - 18:00

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Read the original article

Tags:

Previous Article

FDA denies approval for Theratechnologies’ tesamorelin F8

Gilead’s Trodelvy lung cancer trial fails to increase survival, leading to a sel...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

LEO-152020 by Leo Pharma for Atopic Dermatitis (Atopic ...

Oct 29, 2023

Runimotamab by Genentech USA for Solid Tumor: Likelihoo...

Dec 22, 2023

UK negotiates reform for branded drug payment amidst industry dissatisfaction

UK negotiates reform for branded drug payment amidst in...

May 6, 2023